BioCentury
ARTICLE | Company News

Acorda, NeurogesX deal

July 15, 2013 7:00 AM UTC

Acorda acquired development and commercialization rights in territories that Astellas Pharma Inc. (Tokyo:4503, Tokyo, Japan) does not hold rights, including the U.S., Canada and Latin America, to two neuropathic pain management products - Qutenza capsaicin and NP-1998 (formerly NGX-1998) - from NeurogesX. NeurogesX received $8 million up front and is eligible for $2 million if FDA approves NP-1998 for the cutaneous treatment of painful diabetic neuropathy (PDN) prior to Dec. 31, 2016, and $3 million if net sales of NP-1998 in Acorda's territories reach $100 million in the first 12 months. NeurogesX is not eligible to receive royalties. Qutenza is approved in the U.S. to manage neuropathic pain associated with post-herpetic neuralgia (PHN). NeurogesX discontinued active promotion of Qutenza, a dermal patch containing capsaicin, in March 2012; the product had net U.S. sales of about $2.4 million through the end of 3Q12 and had 2011 net sales of $2.6 million. ...